Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000596067 | SCV000703394 | uncertain significance | not provided | 2016-11-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000596067 | SCV001079151 | benign | not provided | 2023-12-07 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003317294 | SCV004021018 | uncertain significance | not specified | 2023-06-13 | criteria provided, single submitter | clinical testing | Variant summary: LAMA1 c.8447G>A (p.Arg2816Gln) results in a conservative amino acid change located in the Laminin G domain (IPR001791) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00056 in 251482 control chromosomes, predominantly at a frequency of 0.0066 within the East Asian subpopulation in the gnomAD database, including 1 homozygote. This suggests the variant may be a benign polymorphism. To our knowledge, no occurrence of c.8447G>A in individuals affected with Ataxia-Intellectual Disability-Oculomotor Apraxia-Cerebellar Cysts Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as benign, and one as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly benign. |